Skip to main content
Top
Published in: BMC Medical Informatics and Decision Making 1/2023

Open Access 01-12-2023 | Hypertension | Research article

Personalized hypertension treatment recommendations by a data-driven model

Authors: Yang Hu, Jasmine Huerta, Nicholas Cordella, Rebecca G. Mishuris, Ioannis Ch. Paschalidis

Published in: BMC Medical Informatics and Decision Making | Issue 1/2023

Login to get access

Abstract

Background

Hypertension is a prevalent cardiovascular disease with severe longer-term implications. Conventional management based on clinical guidelines does not facilitate personalized treatment that accounts for a richer set of patient characteristics.

Methods

Records from 1/1/2012 to 1/1/2020 at the Boston Medical Center were used, selecting patients with either a hypertension diagnosis or meeting diagnostic criteria (≥ 130 mmHg systolic or ≥ 90 mmHg diastolic, n = 42,752). Models were developed to recommend a class of antihypertensive medications for each patient based on their characteristics. Regression immunized against outliers was combined with a nearest neighbor approach to associate with each patient an affinity group of other patients. This group was then used to make predictions of future Systolic Blood Pressure (SBP) under each prescription type. For each patient, we leveraged these predictions to select the class of medication that minimized their future predicted SBP.

Results

The proposed model, built with a distributionally robust learning procedure, leads to a reduction of 14.28 mmHg in SBP, on average. This reduction is 70.30% larger than the reduction achieved by the standard-of-care and 7.08% better than the corresponding reduction achieved by the 2nd best model which uses ordinary least squares regression. All derived models outperform following the previous prescription or the current ground truth prescription in the record. We randomly sampled and manually reviewed 350 patient records; 87.71% of these model-generated prescription recommendations passed a sanity check by clinicians.

Conclusion

Our data-driven approach for personalized hypertension treatment yielded significant improvement compared to the standard-of-care. The model implied potential benefits of computationally deprescribing and can support situations with clinical equipoise.
Appendix
Available only for authorised users
Literature
1.
go back to reference Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388:1659–724.CrossRef Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388:1659–724.CrossRef
2.
go back to reference Grassi G, Seravalle G, Mancia G. Cardiovascular consequences of poor compliance to antihypertensive therapy. Blood Press. 2011;20:196–203.PubMedCrossRef Grassi G, Seravalle G, Mancia G. Cardiovascular consequences of poor compliance to antihypertensive therapy. Blood Press. 2011;20:196–203.PubMedCrossRef
3.
go back to reference Chobanian AV. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure The JNC 7 report. JAMA. 2003;289:2560.PubMedCrossRef Chobanian AV. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure The JNC 7 report. JAMA. 2003;289:2560.PubMedCrossRef
4.
go back to reference Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison HC, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:e127-248.PubMedCrossRef Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison HC, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:e127-248.PubMedCrossRef
5.
go back to reference Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. AFP. 1998;57:1007. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. AFP. 1998;57:1007.
7.
go back to reference Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2016 update. Circulation. 2016;133:447–54.PubMedCrossRef Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2016 update. Circulation. 2016;133:447–54.PubMedCrossRef
8.
go back to reference Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Zampi I, Gattobigio R, et al. White coat hypertension and white coat effect similarities and differences. Am J Hypertens. 1995;8:790–8.PubMedCrossRef Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Zampi I, Gattobigio R, et al. White coat hypertension and white coat effect similarities and differences. Am J Hypertens. 1995;8:790–8.PubMedCrossRef
9.
go back to reference Pickering TG, Gerin W, Schwartz AR. What is the white-coat effect and how should it be measured? Blood Press Monit. 2002;7:293–300.PubMedCrossRef Pickering TG, Gerin W, Schwartz AR. What is the white-coat effect and how should it be measured? Blood Press Monit. 2002;7:293–300.PubMedCrossRef
10.
go back to reference Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM. Personalized medicine—a modern approach for the diagnosis and management of hypertension. Clin Sci. 2017;131:2671–85.CrossRef Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM. Personalized medicine—a modern approach for the diagnosis and management of hypertension. Clin Sci. 2017;131:2671–85.CrossRef
11.
go back to reference Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertension. 2008;51:1403–19.PubMedCrossRef Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertension. 2008;51:1403–19.PubMedCrossRef
12.
go back to reference Backenroth D, Chase HS, Wei Y, Friedman C. Monitoring prescribing patterns using regression and electronic health records. BMC Med Inform Decis Mak. 2017;17:175.PubMedPubMedCentralCrossRef Backenroth D, Chase HS, Wei Y, Friedman C. Monitoring prescribing patterns using regression and electronic health records. BMC Med Inform Decis Mak. 2017;17:175.PubMedPubMedCentralCrossRef
13.
go back to reference Bertsimas D, Borenstein A, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, et al. Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. Health Care Manag Sci. 2021;24:339–55.PubMedPubMedCentralCrossRef Bertsimas D, Borenstein A, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, et al. Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. Health Care Manag Sci. 2021;24:339–55.PubMedPubMedCentralCrossRef
14.
go back to reference Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol. 2017;69:2657–64.PubMedCrossRef Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol. 2017;69:2657–64.PubMedCrossRef
15.
go back to reference Weiskopf NG, Hripcsak G, Swaminathan S, Weng C. Defining and measuring completeness of electronic health records for secondary use. J Biomed Inform. 2013;46:830–6.PubMedCrossRef Weiskopf NG, Hripcsak G, Swaminathan S, Weng C. Defining and measuring completeness of electronic health records for secondary use. J Biomed Inform. 2013;46:830–6.PubMedCrossRef
16.
go back to reference Goldstein BA, Navar AM, Pencina MJ, Ioannidis JPA. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inform Assoc. 2017;24:198–208.PubMedCrossRef Goldstein BA, Navar AM, Pencina MJ, Ioannidis JPA. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inform Assoc. 2017;24:198–208.PubMedCrossRef
17.
go back to reference Brisimi TS, Xu T, Wang T, Dai W, Paschalidis IC. Predicting diabetes-related hospitalizations based on electronic health records. Stat Methods Med Res. 2019;28:3667–82.PubMedCrossRef Brisimi TS, Xu T, Wang T, Dai W, Paschalidis IC. Predicting diabetes-related hospitalizations based on electronic health records. Stat Methods Med Res. 2019;28:3667–82.PubMedCrossRef
18.
go back to reference Zhu F, Guo J, Li R, Huang J. Robust Actor-Critic Contextual Bandit for Mobile Health (mHealth) Interventions. arXiv:180209714 [cs]. 2018. Zhu F, Guo J, Li R, Huang J. Robust Actor-Critic Contextual Bandit for Mobile Health (mHealth) Interventions. arXiv:180209714 [cs]. 2018.
19.
go back to reference Tewari A, Murphy S. From ads to interventions: contextual bandits in mobile health. In: Mobile health—sensors, analytic methods, and applications. 2017. Tewari A, Murphy S. From ads to interventions: contextual bandits in mobile health. In: Mobile health—sensors, analytic methods, and applications. 2017.
20.
go back to reference Stiglic G, Kocbek P, Fijacko N, Zitnik M, Verbert K, Cilar L. Interpretability of machine learning based prediction models in healthcare. WIREs Data Mining Knowl Discov. 2020;10. Stiglic G, Kocbek P, Fijacko N, Zitnik M, Verbert K, Cilar L. Interpretability of machine learning based prediction models in healthcare. WIREs Data Mining Knowl Discov. 2020;10.
21.
go back to reference Zhang Q, Bai C, Chen Z, Li P, Wang S, Gao H. Smart Chinese medicine for hypertension treatment with a deep learning model. J Netw Comput Appl. 2019;129:1–8.CrossRef Zhang Q, Bai C, Chen Z, Li P, Wang S, Gao H. Smart Chinese medicine for hypertension treatment with a deep learning model. J Netw Comput Appl. 2019;129:1–8.CrossRef
22.
go back to reference Ye X, Zeng QT, Facelli JC, Brixner DI, Conway M, Bray BE. Predicting optimal hypertension treatment pathways using recurrent neural networks. Int J Med Informatics. 2020;139: 104122.CrossRef Ye X, Zeng QT, Facelli JC, Brixner DI, Conway M, Bray BE. Predicting optimal hypertension treatment pathways using recurrent neural networks. Int J Med Informatics. 2020;139: 104122.CrossRef
23.
go back to reference Mandair D, Tiwari P, Simon S, Colborn KL, Rosenberg MA. Prediction of incident myocardial infarction using machine learning applied to harmonized electronic health record data. BMC Med Inform Decis Mak. 2020;20:252.PubMedPubMedCentralCrossRef Mandair D, Tiwari P, Simon S, Colborn KL, Rosenberg MA. Prediction of incident myocardial infarction using machine learning applied to harmonized electronic health record data. BMC Med Inform Decis Mak. 2020;20:252.PubMedPubMedCentralCrossRef
24.
go back to reference Chen R, Paschalidis IC. Distributionally Robust Learning. Foundations and Trends® in Optimization. 2020;4:1–243. Chen R, Paschalidis IC. Distributionally Robust Learning. Foundations and Trends® in Optimization. 2020;4:1–243.
25.
go back to reference Cover T, Hart P. Nearest neighbor pattern classification. IEEE Trans Inf Theory. 1967;13:21–7.CrossRef Cover T, Hart P. Nearest neighbor pattern classification. IEEE Trans Inf Theory. 1967;13:21–7.CrossRef
27.
go back to reference Chen R, Paschalidis IC. A robust learning approach for regression models based on distributionally robust optimization. J Mach Learn Res. 2018;19:517–64.PubMedPubMedCentral Chen R, Paschalidis IC. A robust learning approach for regression models based on distributionally robust optimization. J Mach Learn Res. 2018;19:517–64.PubMedPubMedCentral
28.
go back to reference Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire J-P. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005;19:607–13.PubMedCrossRef Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire J-P. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005;19:607–13.PubMedCrossRef
29.
go back to reference Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093–100.PubMedCrossRef Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093–100.PubMedCrossRef
30.
go back to reference Wong MCS, Jiang JY, Gibbs T, Griffiths SM. Factors associated with antihypertensive drug discontinuation among Chinese patients: a cohort study. Am J Hypertens. 2009;22:802–10.PubMedCrossRef Wong MCS, Jiang JY, Gibbs T, Griffiths SM. Factors associated with antihypertensive drug discontinuation among Chinese patients: a cohort study. Am J Hypertens. 2009;22:802–10.PubMedCrossRef
31.
go back to reference Taddei S. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Am J Cardiovasc Drugs. 2015;15:185–94.PubMedCrossRef Taddei S. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Am J Cardiovasc Drugs. 2015;15:185–94.PubMedCrossRef
32.
go back to reference Chen R, Paschalidis I. Selecting optimal decisions via distributionally robust nearest-neighbor regression. In: Advances in Neural Information Processing Systems. Curran Associates, Inc.; 2019. Chen R, Paschalidis I. Selecting optimal decisions via distributionally robust nearest-neighbor regression. In: Advances in Neural Information Processing Systems. Curran Associates, Inc.; 2019.
33.
go back to reference Tibshirani R. Regression shrinkage and selection via the Lasso. J Roy Stat Soc: Ser B (Methodol). 1996;58:267–88. Tibshirani R. Regression shrinkage and selection via the Lasso. J Roy Stat Soc: Ser B (Methodol). 1996;58:267–88.
34.
go back to reference Breiman L, Friedman JH, Olshen R, Stone CJ. Classification and Regression Trees. 1984. Breiman L, Friedman JH, Olshen R, Stone CJ. Classification and Regression Trees. 1984.
36.
go back to reference Li N, Zhou H, Tang Q. Red blood cell distribution width: a novel predictive indicator for cardiovascular and cerebrovascular diseases. Dis Markers. 2017;2017: e7089493.CrossRef Li N, Zhou H, Tang Q. Red blood cell distribution width: a novel predictive indicator for cardiovascular and cerebrovascular diseases. Dis Markers. 2017;2017: e7089493.CrossRef
37.
go back to reference Tanindi A, Topal FE, Topal F, Celik B. Red cell distribution width in patients with prehypertension and hypertension. Blood Press. 2012;21:177–81.PubMedCrossRef Tanindi A, Topal FE, Topal F, Celik B. Red cell distribution width in patients with prehypertension and hypertension. Blood Press. 2012;21:177–81.PubMedCrossRef
38.
go back to reference Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–34.PubMedCrossRef Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–34.PubMedCrossRef
39.
go back to reference Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol. 2019;73:2584–95.PubMedPubMedCentralCrossRef Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol. 2019;73:2584–95.PubMedPubMedCentralCrossRef
40.
go back to reference James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.PubMedCrossRef James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.PubMedCrossRef
41.
go back to reference Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Blood Press. 2013;22:193–278.CrossRef Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Blood Press. 2013;22:193–278.CrossRef
42.
go back to reference Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124:1045–60.PubMedCrossRef Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124:1045–60.PubMedCrossRef
43.
go back to reference Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the optimise randomized clinical trial. JAMA. 2020;323:2039–51.PubMedPubMedCentralCrossRef Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the optimise randomized clinical trial. JAMA. 2020;323:2039–51.PubMedPubMedCentralCrossRef
44.
go back to reference Sanyal C, Turner JP, Martin P, Tannenbaum C. Cost-effectiveness of pharmacist-led deprescribing of NSAIDs in community-dwelling older adults. J Am Geriatr Soc. 2020;68:1090–7.PubMedCrossRef Sanyal C, Turner JP, Martin P, Tannenbaum C. Cost-effectiveness of pharmacist-led deprescribing of NSAIDs in community-dwelling older adults. J Am Geriatr Soc. 2020;68:1090–7.PubMedCrossRef
45.
go back to reference Turner JP, Sanyal C, Martin P, Tannenbaum C. Economic Evaluation of sedative deprescribing in older adults by community pharmacists. J Gerontol A Biol Sci Med Sci. 2021;76:1061–7.PubMedCrossRef Turner JP, Sanyal C, Martin P, Tannenbaum C. Economic Evaluation of sedative deprescribing in older adults by community pharmacists. J Gerontol A Biol Sci Med Sci. 2021;76:1061–7.PubMedCrossRef
46.
go back to reference Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the united states. Hypertension. 2019;73:424–31.PubMedCrossRef Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the united states. Hypertension. 2019;73:424–31.PubMedCrossRef
47.
go back to reference Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Original papers. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertension. 2002;4:393–404.CrossRef Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Original papers. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertension. 2002;4:393–404.CrossRef
48.
go back to reference Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, et al. Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attack. Am J Med. 2015;128:707-714.e2.PubMedPubMedCentralCrossRef Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, et al. Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attack. Am J Med. 2015;128:707-714.e2.PubMedPubMedCentralCrossRef
49.
go back to reference Sousa CT, Ribeiro A, Barreto SM, Giatti L, Brant L, Lotufo P, et al. Racial differences in blood pressure control from users of antihypertensive monotherapy: results from the ELSA-Brasil study. Arq Bras Cardiol. 2022;118:614–22.PubMedPubMedCentralCrossRef Sousa CT, Ribeiro A, Barreto SM, Giatti L, Brant L, Lotufo P, et al. Racial differences in blood pressure control from users of antihypertensive monotherapy: results from the ELSA-Brasil study. Arq Bras Cardiol. 2022;118:614–22.PubMedPubMedCentralCrossRef
50.
go back to reference Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond E, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Archiv Internal Med. 2001;161:965–71.CrossRef Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond E, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Archiv Internal Med. 2001;161:965–71.CrossRef
51.
go back to reference Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, et al. A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. Am Heart J. 2018;204:102–8.PubMedPubMedCentralCrossRef Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, et al. A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. Am Heart J. 2018;204:102–8.PubMedPubMedCentralCrossRef
Metadata
Title
Personalized hypertension treatment recommendations by a data-driven model
Authors
Yang Hu
Jasmine Huerta
Nicholas Cordella
Rebecca G. Mishuris
Ioannis Ch. Paschalidis
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Medical Informatics and Decision Making / Issue 1/2023
Electronic ISSN: 1472-6947
DOI
https://doi.org/10.1186/s12911-023-02137-z

Other articles of this Issue 1/2023

BMC Medical Informatics and Decision Making 1/2023 Go to the issue